Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Sponsor: Intra-Cellular Therapies, Inc.
A PHASE3 clinical study on Major Depressive Disorder, this trial is completed. The trial is conducted by Intra-Cellular Therapies, Inc. and has accumulated 13 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
May 2025 — Jun 2025 [monthly]
Completed PHASE3
-
Apr 2025 — May 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Apr 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE3
-
Oct 2021 — May 2022 [monthly]
Recruiting PHASE3
First recorded
Sep 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Intra-Cellular Therapies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .